Myeloproliferative neoplasms are a category of diseases that have been traditionally amenable to allogeneic hematopoietic progenitor cell transplantation. Current developments in drug therapy have delayed transplantation for more advanced phases of the disease, especially for patients with CML, whereas transplantation remains a mainstream treatment modality for patients with advanced myelofibrosis and chronic myelomonocytic leukemia. Reduced-intensity conditioning has decreased the treatmentrelated mortality, and advances in the use of alternative donors for transplantation could extend the use of this procedure to an increasing number of patients with improved safety and efficacy. Here we review the current knowledge about allogeneic transplantation for myeloproliferative neoplasms and discuss the most important aspects to be considered when contemplating transplantation for patients with these diseases. Janus kinase 2 inhibitors offer the promise to improve spleen size and performance of patients with myelofibrosis and extend transplantation for patients with more advanced disease.
• A differential approach should be undertaken for patients with different myeloproliferative neoplasms (MPNs) requiring allogeneic transplantation.
• BU-based conditioning appears to be associated with improved transplant outcomes for patients with MPNs.
• Patients with myelofibrosis are older and benefit from the reduced-intensity conditioning, whereas patients with CML and chronic myelomonocytic leukemia may require more intense (myeloablative) conditioning.
• Patients with advanced polycythemia vera/essential thrombocythemia have better outcomes and should be considered for transplantation before progression to acute leukemia or advanced phases of the disease.
• For patients with known mutations, novel targeted approaches to decrease disease burden before transplant and prevent disease relapse post transplant are warranted.
INTRODUCTION
Myeloproliferative neoplasms (MPNs) generally refer to a group of clonal chronic hematologic disorders with both distinct and overlapping features. The 2008 WHO classification divides these diseases into two broad categories-classical and atypical MPNs. 1 The classical MPNs are CML, idiopathic/primary myelofibrosis (MF), polycythemia vera (PV), essential thrombocythemia (ET), systemic mastocytosis, chronic neutrophilic leukemia (CNL) and chronic eosinophilic leukemia (CEL), 2 whereas atypical MPNs are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia and atypical CML BCR-ABL negative. The discovery of the BCR-ABL inhibitor imatinib (Gleevec) has revolutionized the treatment of CML and has made allogeneic hematopoietic progenitor cell transplantation (AHPCT) a second choice for patients who failed treatment with tyrosine kinase inhibitors (TKIs), or have progressed to accelerated or blast phase. More recently, several JAK2V617F inhibitors have shown activity in idiopathic MF, primarily related to reduced symptoms and decrease in spleen size. These effects appear to be independent of the presence of this mutation and, clearly, only partially recapitulate the great success for imatinib for treatment of CML. Nevertheless, the advent of novel agents hold the promise to further improve the medical treatment for these diseases, and will pose a continuous challenge to the alternative treatment option, which is allogeneic transplantation. This article will focus on the treatment of myeloproliferative neoplasms using hematopoietic progenitor cell transplantation in the era of novel TKIs.
AHPCT remains the only curative modality available, 4 it was unfortunately fraught with significant morbidity and mortality. Hehlmann et al. 5 initially reported on patients with chronic phase CML who were randomized based on donor availability, to allogeneic transplantation vs the drug treatment. 5 This group observed that patients on the drug treatment arm had better survival in the first 8 years owing to very low treatment-related mortality in this group. 5 However, after the 8-year follow-up survival appeared better with transplant because of continued relapse in the non-transplant group. 5 The randomized clinical trial of IFN vs STI-571 (IRIS trial) showed that, for the patients who were on imatinib, the EFS and OS were 81% and 85%, respectively, and when only CML-related deaths before allogeneic transplantation were taken into consideration, the OS increased to 93%. 6 Before the approval of imatinib, CML was the most common indication for AHPCT in the first chronic phase, with an OS of 50% at 10 years. 7 Since imatinib became available, several second-(nilotinib and dasatinib) and third-(ponatinib) generation TKIs have been developed. A few drugs specifically target resistant mutations such as T315I present in a subgroup of patients with CML. These mutations may develop at the time of resistance to imatinib or other TKIs, and the development of such mutations may signal the imminent need for AHPCT.
Changes in transplantation for CML Several reports have documented a decline in annual transplantation rates for CML. The German Registry of SCT group observed a 28% reduction in annual transplant rates between 1998 and 2004, 8 similar to reports form the Center for International Blood & Marrow Transplant Research (CIBMTR) and European Bone Marrow Transplantation. 9 This reduction was seen across the board in patients in first chronic phase. However, an increase in the number of transplants was seen in more advanced CML patients, such as those in second chronic phase or beyond (accelerated or blast phase), with the CIBMTR documenting an increase from 21 to 41% from 1999 to 2003. 10 Allogeneic transplantation is thus now reserved for patients who have progressed to accelerated or blast phase, to chronic phase CML patients who have failed at least second-generation TKIs and to those who have developed resistant mutations to TKI, such as T315I mutation, with limited drug treatment options.
An important question is whether treatment with TKIs affects transplant outcomes or not. In a recent CIBMTR study, Lee et al. 11 showed, on 1309 patients (409 treated with imatinib before transplant), that patients who had received a TKI before undergoing an allogeneic transplant did not have worse outcomes. 11 The 3-year OS was 72% vs 65% (P = 0.07) in patients with prior TKI vs no TKI, suggesting that transplant outcomes were not compromised by the use of drug therapy before transplantation.
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The German CML group published an interim analysis of patients who were transplanted early for high-risk disease, those who had failed imatinib and those who had advanced disease. A total of 84 patients received an allogeneic transplantation. 12 This group observed a complete molecular remission rate of 88% after AHPCT and a treatment-related mortality of 8%. 12 The 3-year OS in patients with imatinib failure was 94%, whereas those with advanced disease had an OS of 59%. 12 In the original IRIS study, secondary resistance was deemed to occur at a rate of 4% annually, and was associated usually with a mutation in the BCR-ABL1 kinase domain. 6, 13, 14 Second-and third-generation TKIs have shown responses in patients with resistant mutations. 14, 15 Recently, ponatinib has been approved for patients with T315I mutation based on a phase II study, which showed a 57% major cytogenetic response. 15 Allogeneic transplantation has been shown to be of benefit in patients who harbor BCR-ABL1 KD mutations, including the T315I mutation. 14, 16 A retrospective analysis of patients transplanted with this mutation compared with a historical cohort showed that these patients appear to fare better with 2-year OS rates for chronic phase, accelerated phase, blast phase and Ph + ALL of 59%, 67%, 30% and 25%, respectively. 16, 17 Only a few studies have analyzed transplant outcomes of patients who transformed to accelerated or blast phase. Jiang et al. 18 showed that patients with accelerated phase disease had superior outcomes with transplantation, compared with patients who received imatinib only with a 6-year PFS of 71.7% vs 39.2% (P = 0.035) and 6-year OS and of 83.3% vs 51.4% (P = 0.023), with factors such as increased percentage of peripheral blasts and longer CML disease durations as adverse risk factors. 18 It has also been reported that, in patients with advanced phase disease (AP or BP), the outcomes are worse post transplant in patients with BCR-ABL1 mutations.
14 Jabbour et al. 14 reported a 2-year OS of 46% vs 72% (P = 0.12) in patients with BCR-ABL1 mutations vs no mutations.
14 Our group evaluated the outcomes of patients in second chronic phase after they progressed to lymphoid or myeloid blast phase CML and observed a long-term survival of 42% with no significant differences in outcomes for patients who progressed with lymphoid vs myeloid blast crisis. 19 Alternative donor transplantation for CML More recently, alternative donors are increasingly used for patients without a matched donor with good results. Haploidentical donors may expand the use of transplantation for patients with advanced disease. Huang and co-workers 20 initially reported results on 93 patients treated with unmanipulated haploidentical transplantation for patients with CML who lack a matched-related donor. All patients received BuCy2 regimen. The treatment-related mortalities at day 100 and 1-year post transplant were only 8.7% and 20.7%, whereas 4-year PFS for patients in CP2, AP and BP were 85%, 73% and 61.5%, respectively. 20 Our recent experience with haploidentical transplantation is also very encouraging. We have recently reported results of the first 10 treated patients with advanced CML (seven progressed to BP, three to AP) with a haploidentical transplant using post transplantation CY, at our institution. All 10 patients engrafted the donor cells promptly and none died of treatment-related mortality. Four patients subsequently relapsed, three not in second chronic phase at the time of transplant. Overall six patients survived, with five in molecular remission after a median follow-up of 22 months. 21 In summary, allogeneic transplantation for patients with CML is now performed for patients with more advanced disease, who progressed to accelerated of blast phase and are resistant or intolerant to TKIs. Alternative donor transplantation can now be performed safely for these patients and will likely extend this form of treatment to virtually all patients in need.
IDIOPATHIC/PRIMARY MF
MF is a Ph-chromosome-negative myeloproliferative neoplasm of unclear etiology. Whether there is a primary causal mutation leading to MF is yet to be determined; however, a number of mutations have been found to be associated with this condition, among which are Janus kinase 2 (JAK2) and MPL mutations. [22] [23] [24] While drug therapy is currently being explored, and despite recent Food and Drug Administration approval of ruxolitinib, a JAK1/2 inhibitor has been shown to improve MF symptoms, and spleen size. 25 However, the only curative treatment modality for MF remains allogeneic transplantation.
Scoring systems Prognostic scoring systems have long helped the decision to proceed with transplant and have been recently refined.
A detailed list of scoring systems used to decide which patients should be considered for transplantation is provided in Table 1 . The International Prognostic Scoring System (IPSS) for primary MF, and subsequent improvements most recently with the Dynamic IPSS Plus, allowed a better discrimination of the risk category and helped the treating physician make decisions with regard to observation, initiation of drug therapy and help guide timing of allogeneic transplantation. [26] [27] [28] The DIPSS-Plus classifies patients into low-risk, intermediate-risk 1, intermediate-risk 2 and high-risk disease. 27 This scoring system uses specific patient risk factors to predict leukemia-free survival and OS. The DIPPS-Plus was an improvement on IPSS and DIPSS by incorporating patient's platelet count, transfusion status and karyotype into the model, and was found to better predict the patient outcomes. The current recommendation is that patients in the intermediate-risk 2 and high-risk group be evaluated for allogeneic transplantation as soon as possible as the median survival in these two groups was reported to be 35 and 16 months, respectively. 27 This scoring system also appreciates the risk of leukemic transformation (LT), with the 5-year risk of transformation of 6% in the low-risk group and 18% in the high-risk group category. The 10-year leukemiafree survivals were 12% and 31% in the low-and high-risk group, respectively. 27 Only a few reports have attempted to investigate scoring systems to predict outcomes for patients with MF after allogeneic transplantation. Bacigalupo et al. 29 reported on a scoring system based on transfusion requirement (420 U of packed red blood cells), spleen size (422 cm) and donor type (matched sibling vs alternative donor). 29 Patients were subsequently categorized into two groups: low and high risk. These investigators observed a higher TRM in those with high-risk (41%) vs the low-risk group (8%) and a relapse-related death of 12% vs 41% in the low-risk vs high-risk group (P = 0.02). 29 The 5-year OS for all patients was 45%, ranging from 77% in the low-risk group to only 8% in the high-risk group of patients (P o0.001). Although based on a relatively small number of patients and not validated, this scoring system appears to discriminate well between the proposed risk groups and could be a useful tool to better select candidates for allogeneic transplantation.
Allogeneic transplantation for patients with MF is usually limited by the more advanced age of the patients and the fact that they have associated comorbidities, which are known risk factors for increased morbidity and mortality in ASCT. The 3-year OS in patients with MF post transplant was reported to be in the range of 30-50%, whereas TRM can be as high as 40%. 30 There have been different factors attributed to this variation, one of which is the intensity of the conditioning regimen used. In a recent retrospective report from the United Kingdom, outcomes of 51 patients who received either a myeloablative (MA) or reducedintensity conditioning (RIC) AHPCT for MF were compared; this group observed no significant difference in 3-year OS or PFS (OS 44% vs 31%, PFS 44% vs 24%) in the MA vs the RIC group. 31 Interestingly, there was no significant difference in non-relapse mortality rate between the two groups; however, the relapse rate was lower (12%) in the MA group vs RIC (46%) with a strong trend toward significance (P = 0.06), likely not reached owing to the relatively small number of patients. These results were almost similar to the results reported by the CIBMTR study group, in which a 3-year disease-free survival (DFS) of 39%, and 1-year TRM of 15% in patients with matched sibling donors who received RIC transplantation was found. However, patients who had an unrelated donor appeared to have worse transplant outcomes with a DFS and TRM of 17% and 49%, respectively. 32 In a multicenter study of RIC before allo-SCT showed that in patients who had a fully matched-unrelated donor, there was no significant difference in non-relapse mortality when compared with HLAmatched sibling donors, 13% vs 10%. 33 For mismatched donors, the non-relapse mortality rate was significantly higher at 38%. 33 These results were comparable with preliminary results from the Phase II MPD-RC 101 prospective clinical trial, where the investigators observed a higher TRM owing to a higher rate of primary or secondary graft failure in patients who had unrelated donor transplants and received RIC with fludarabine-and melphalan-based conditioning. 34 The role of JAK2V617F mutation in allogeneic transplantation for MF JAK2V617F mutation is found in up to 50% of patients with MF. 24 JAK2V617F mutation has been suggested to be an adequate biomarker to detect residual disease and monitor for disease relapse post transplant. 35, 36 In a recent study, Alchalby et al.
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observed that the 5-year OS was improved in those that were JAK2 wild type vs those who had the mutation, 44% vs 70% (P = 0.007), suggesting that patients with JAK2V617F mutation could have worse outcomes after AHPCT. 36 This group also evaluated JAK2 mutational status at 3-month intervals post transplant and observed that clearance of JAK2 mutation was associated with a decreased risk of relapse. 36 Patients who had cleared JAK2V617F had a 5% risk of relapse vs 31% for those who were still positive at 3 months. This risk was also shown to increase at 6 months. 36 Moreover, reappearance of JAK2V617F mutation post transplant was very likely to be associated with relapsed disease, unless rapid taper of immune suppression or donor lymphocyte infusion was used.
It has become clear that patients with MF do not tolerate very intense conditioning owing to their more advanced age and associated comorbidities. Our group has explored RIC transplantation for patients with MF using BU-based conditioning. Patients received higher (AUC 4000 μmol/min or 100 mg/m 2 for 4 days) and lower (130 mg/m 2 for 2 days) BU doses. Fludarabine dose was the same in both groups at 40 mg/m 2 for 4 days. We observed that patients who received higher BU doses had a better 3-year OS survival of 75% vs 60% in the low-dose BU group. 37 EFS was also significantly better at 61% vs 27% owing to a lower cumulative incidence of relapse of 29% in the high-dose BU vs 53% in the low-dose BU group. 37 Interestingly, the incidence of non-relapse mortality was not increased with higher doses of BU, suggesting that a reduced toxicity conditioning sufficient to achieve sustained engraftment of donor cells could be most effective in producing long-term remissions with low treatment-related mortality in patients with MF. 37 Transplantation for MF with LT The outcomes for patients with MF with LT have been particularly poor with conventional therapy, with single institutional studies reporting a median OS of approximately 3 months, whether patients received treatment with chemotherapy or no treatment at all. 38 LT occurs in 8 to 23% of patients with MF in the first 10 years after a diagnosis, with a median of 31 months. 38, 39 We have shown that patients with MF and LT can achieve durable long-term remission after transplant. 39 Our group initially reported the MD Anderson experience on 14 patients who had progressed to acute leukemia. Most patients received fludarabine-melphalan RIC conditioning. All patients achieved remission after transplant and long-term survivors also received cytotoxic chemotherapy before transplant. After a median follow-up of 31 months, OS and PFS were 49% and 33%, respectively. 39 Kennedy et al. 40 recently reported results of a retrospective study for patients with MPNs with LT, who received induction therapy followed by allogeneic transplantation. 40 The 2-year OS survival was 47% for the cohort of patients who received a transplant, compared with an OS of 15% for those who did not receive a transplant. 40 Factors significantly associated with worse outcomes in patients who were treated with the intent of a cure were patient's poor performance status, percentage of BM blast 450% and the presence of three or more Transplantation for MPNs in the Era of TKIs K Adekola et al Abbreviations: Abn. = abnormalities; ALC = absolute lymphocyte count; AP = accelerated phase; BP = blast phase; CMML = chronic myelomonocytic leukemia; ET = essential thrombocythemia; IMC = immature myeloid cell; IPSS = International Prognostic Scoring System; MF = myelofibrosis; N/A = not applicable; PV = polycythemia vera; SMF = secondary myelofibrosis; TKI = tyrosine kinase inhibitors; MDAPS = MD Anderson Prognostic Score; PLT = platelet count .
Transplantation for MPNs in the Era of TKIs K Adekola et al cytogenetic abnormalities. 40 These two studies suggest that there is a benefit to transplanting patients with MF and other MPNs that have transformed to acute leukemia ,and selected patients may benefit from this procedure after adequate cytoreduction. 39, 40 In summary, transplantation for MF should probably be performed with an ablative yet reduced-intensity conditioning regimen, although the optimal type and intensity remains unclear. JAK2 inhibitors offer the promise to improve symptoms of patients with this disease and make more patients eligible for transplantation.
CHRONIC MYELOMONOCYTIC LEUKEMIA CMML is one of the more rare and atypical MPNs, which under the most recent WHO 2008 criteria is classified in the myeloproliferative/myelodysplastic syndrome category. 41 It is divided into two groups based on the percentage of BM and PB blasts: CMML type 1 has o 10% BM and o5% PB blasts, and CMML type 2 has 10-19% BM and 5-19% PB blasts. 42 CMML has been notoriously resistant to medical therapy and there are few studies designed exclusively for treatment of this disease. Multiple therapeutic approaches have been used and various pharmacotherapeutic agents have been tried, such as cytotoxic chemotherapy, TKIs (imatinib), immunomodulating agents such as lenalidomide, hypomethylating agents, histone deacetylase inhibitors and farnesyl transferase inhibitors, all with modest results. 43, 44 Several models have been proposed to determine prognosis of this disease, and the most recent one was based on the registry data from the Spanish database. In this CMML-specific prognostic scoring system, patients were stratified based on cytogenetics, patient characteristics, lactate dehydrogenase and hematologic indices. 45 In regards to cytogenetics, three cytogenetic risk categories were identified, with significant differences in 5-year survival (Po0.001); low risk composed of patients with normal karyotype, or loss of Y chromosome with 35% survival at 5 years, high-risk composed of patients with trisomy 8, chromosome 7 anomalies and patients with complex karyotype (4% survival at 5 years), whereas intermediate risk composed of patients who did not belong to any of the two groups with 26% survival at 5 years. 45 The MD Anderson group analyzed outcomes of approximately 200 patients with CMML treated at our institution and described a new prognostic scoring system for this disease, subsequently validated in other studies. 46 The factors significantly associated with outcome were Hb o12 g/dL, presence of circulating immature myeloid cells, absolute lymphocyte count 42.5 × 10 9 /L and marrow blasts ⩾ 10%. Four prognostic groups were identified based on the number of factors present, with a median survival of 24, 15, 8 and 5 months. Because of very poor outcomes (median survival 12 months for the whole cohort) overall and no good alternative treatment options, we currently advocate allogeneic SCT in almost all patients eligible for transplantation.
While medical treatment has been generally ineffective, allogeneic transplantation, similar to other MPNs, can cure this disease. However, transplant outcomes for these patients are, in general, worse than other MPDs. Several reports described outcomes of patients with CMML. Results of a multicenter study were reported by Kroger et al. 47 in 2002. This group studied 50 patients with CMML (18 with 45% blasts at transplantation), 43 had a matched-related donor transplant and 40 had BM as stem cell source. 47 All patients received MA conditioning with or without TBI. The 5-year estimated OS and DFS were only 21% and 18%, respectively, whereas relapse rate was 49%. This high relapse rate suggested that more intense conditioning might be needed for these patients. 47 Factors that appeared to improve DFS (while it did not reach statistical significance) were the development of acute GVHD, male donor, early transplantation in disease course and the use of unmanipulated grafts. 47 Krishnamurthy et al. 48 reported a smaller retrospective study of 18 patients, majority of who had received RIC (17 patients), with T-cell depletion. In their cohort, the 3-year OS and non-relapse mortality rate were both 31% with a relapse rate of 47%. 48 A large retrospective study analyzed 283 CMML patients from the European Bone Marrow Transplantation database and evaluated factors that affected patient outcomes. 49 The non-relapse mortality rate overall was 37%, reportedly lower in those transplanted after 2002 and who had a PB SCT (P = 0.015 and 0.023, respectively). 49 There were no significant differences in OS and relapse-free survival (RFS) with regard to conditioning regimen used, type of the donor/stem cell source or the use of T-cell depletion. 49 This group observed that most patients (61%) died of transplant-related complications, and 32% were related to the underlying disease ( Table 2) .
The Fred Hutchinson Cancer Research Center initially reported results of 21 patients with CMML treated with MA conditioning, predominantly TBI based. 50 This group reported a DFS of 39% at 3 years and relapse rate of only 25%. The probability of survival was improved if patients were transplanted earlier in the course of their disease. 50 The same group updated results and reported long-term outcomes on 85 patients with CMML. 51 They observed a DFS of 40% at 10 years, with a median time to relapse of 183 days. The non-relapse mortality was 33% at 2 years and 34% 10 years post transplant. The probability of disease progression was only 24% at 2 years and 27% at 10 years. Predictors of better RFS were good-risk cytogenetic category, low comorbidity index, high pretransplant hematocrit and lower age. Although grades 3-4 acute GVHD occurred in 21 patients (26%), and chronic GVHD in 37 patients (44%) at 2 years, only two patients died as a result of GVHD. 51 Encouragingly, conditioning with targeted BU was associated with better outcomes, although this was not statistically significant.
We reported outcomes of patients with CMML treated at our institution. A total of 279 patients were evaluated, with 9% of patients undergoing an ASCT. 52 We have found that the patients who received an allogeneic transplant survived longer with OS at 2 and 5 years of 40.5% and 24.3%, respectively, compared with 34.3% and 8.9%, respectively, for patients who did not receive a transplant. Predictors of worse outcomes after transplant were the presence of splenomegaly, poor-risk cytogenetics and a high IPSS score of ⩾ 1.5. Preliminary analysis of the first 83 patients treated with allogeneic transplantation at MD Anderson Cancer Center showed, in multivariate analysis, that factors significantly associated with better survival were the use of a matched-related donor and the development of chronic GVHD, whereas severe grade 3-4 acute GVHD and ⩾ 20% blasts at transplant negatively impacted outcomes. In our analysis, cytogenetic risk category did not have a significant impact on transplant outcomes (unpublished data).
In summary, while allogeneic transplantation remains the only treatment modality that ensures long-term survival for patients with CMML, results are far from optimal. It appears that persistent high treatment-related mortality (although improved over the past years) and higher relapse rates remain important limitations. Available data suggest that MA conditioning, probably BU based, and early transplantation is likely needed to successfully treat this disease. Novel approaches that will minimize treatment-related mortality are needed for these patients.
PV/ET PV and ET are relatively indolent myeloproliferative diseases that usually have a prolonged course spanning many years, as patients do well on multiple treatment modalities such as phlebotomy, hydroxyurea and, more recently, on JAK2 inhibitors. Up to 95% of patients with PV harbor the JAK2V617F compared with approximately half the patients with ET. 24, 53 Despite their relatively long 54 56 Abbreviations Transplantation for MPNs in the Era of TKIs K Adekola et al course, these diseases have the ability to transform potentially into MF and AML, making them candidate diseases for allogeneic transplantation. Patients with PV or ET transformed to MF may have better outcomes than those with primary/idiopathic MF. 54, 55 There are very few reports on the use of HPCT for advanced PV or ET. Platzbecker et al. 55 reported transplant outcomes for 25 patients with PV (n = 12) and ET (n = 13). Approximately twothirds of patients were alive after a median follow-up of 57 months. The median duration of disease was 150 months in patients who survived vs 252 months in those who died, which suggested, again, that increase in the interval from diagnosis to transplant was associated with an increased risk of dying (hazard ratio = 1.87). 55 Another study reported transplant outcomes for patients with post-ET (n = 18), post-PV (n = 12) MF and other MPNs. 56 This group showed that patients with post-PV and post-ET MF had a significantly lower rate of treatment-related mortality and higher probability of survival compared with patients with other MPNs (P = 0.03). 56 A large retrospective CIBMTR analysis confirmed these very good outcomes and analyzed 117 patients who received an allogeneic transplantation for advanced PV and ET between 1990 and 2007. 57 This study also included patients whose disease had transformed to MF; however, 52% of ET and 50% of PV patients did not have transformed disease. Most patients received MA conditioning (n = 80), whereas a subgroup received RIC and non-MA transplants (n = 37). The 1-and 5-year OS for ET were 69% and 55%, respectively, whereas for PV were both 71%. The treatmentrelated mortality at 100 days for patients with ET and PV was 16% and 22%, respectively. The most common causes of death were organ toxicity (50% for ET and 38% for PV patients). Relapse rates at 1 year for the ET and PV patients were only 11% and 25%, respectively. 57 In summary, transplantation for advanced PV and ET is feasible and should probably be performed with a reduced-intensity conditioning regimen before LT, 'spent phase' or major organ dysfunction is encountered.
CONCLUSIONS AND FUTURE DIRECTIONS
Although AHPCT remains the only curative option for patients with myeloproliferative diseases, and despite improvement in outcomes owing to advancements in HLA typing, management of peritransplant infectious complications, immunosuppression and GVHD prevention and therapy, this procedure is still fraught with significant morbidity and mortality, especially in older patients with advanced disease. Thus, the decision to proceed with an allogeneic SCT should be individualized and a more rigorous selection of candidates for transplant is required. It is important to stratify patients and take into consideration existing data for each specific disease, patient's treatment goals and expected quality of life when making the recommendation to proceed with an allogeneic SCT in an individual with a myeloproliferative neoplasm. While CML patients are younger and would tolerate more intense conditioning, patients with MF are older and transplantation using a fully intense MA conditioning is associated with unacceptable treatment-related mortality. For these patients, reduced-intensity conditioning appears to be better tolerated; however, the least toxic conditioning that achieves elimination of the disease to ensure optimal long-term outcomes remains to be determined. Transplantation in the early stages of the disease, before significant organ damage and certainly before transformation to acute leukemia is important, as a more advanced disease is associated, in general, with increased toxicity, higher treatmentrelated mortality and worse outcomes.
For patients with MF, treatment with JAK2 inhibitors before transplant may ameliorate splenomegaly and improve patient's performance status, while maintenance post transplant for CML with TKIs and with JAK2 inhibitors for MF should be investigated in an attempt to prevent disease relapse post transplant.
